undamentalytics Newsletter
Sign in

Nexalin Technology, Inc. revenue

Nexalin Technology, Inc.'s revenue was $301,647 in fiscal 2025, up 78.8% on the year before. Since fiscal 2021 ($144,065) it has grown at a compound 20.3% a year. Over the last twelve months it was $217,155.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1441,321111169302217
Growth on the year before—+817.2%−91.6%+52.3%+78.8%—
Gross profit12395885132240187

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Device Sales $136,000 45.1% ▲ 145.0%
Equipment $89,042 29.5% ▲ 135.4%
Licensing Fee $49,114 16.3% ▼ 29.3%
Other $27,491 9.1% ▲ 366.4%
Geography
Region Revenue YoY
China $190,301 ▲ 123.2%
International $190,301 ▲ 123.2%
United States $111,346 ▲ 33.4%

These categories overlap or exclude eliminations, so shares aren't shown.

From Nexalin Technology, Inc.'s 10-K filed March 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Health Care Equipment: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Nexalin Technology, Inc. $217,155 24.2% -30.6%
Qtrex Quantum Ltd. $289,000 — —
Pavmed Inc. $112,000 -89.0% -49.6%
Phaos Technology Holdings (cayman) Ltd $102,806 -18.2% —
Itonic Holdings Ltd $523,031 16.7% —
Co-diagnostics, Inc. $721,387 -28.1% -53.8%

Compare with peers

Head to head: NXL vs QTEXNXL vs PAVMNXL vs POAS

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Nexalin Technology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Nexalin Technology, Inc.